Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion

Purpose To evaluate the prognostic factors and outcomes of dexamethasone intravitreal implant (DEX implant) for intravitreal bevacizumab refractory macular edema secondary to branch retinal vein occlusion (BRVO). Methods This was a retrospective, interventional case series. Medical records were reviewed, and a total of 38 eyes that were treated with DEX implant for macular edema secondary to BRVO that did not respond to at least two consecutive intravitreal bevacizumab injections (IBIs) were included. Best-corrected visual acuity (BCVA), central subfield macular thickness, and central subfoveal choroidal thickness were evaluated at baseline, 2 months, and 6 months after DEX implantation. Results Patients had undergone an average of 6.32 ± 4.66 prior IBI treatments. The average BCVA improved from 0.53 ± 0.26 to 0.41 ± 0.25 and 0.44 ± 0.23 logarithm of the minimal angle of resolution (logMAR) at 2 and 6 months, respectively (p < 0.001). The average central subfield macular thickness was 504.00 ± 121.54 µm at baseline and changed to 293.21 ± 74.17 µm and 427.28 ± 119.57 µm at 2 and 6 months, respectively (p < 0.001 and p = 0.002). Average central subfoveal choroidal thickness was 237.46 ± 92.21 µm at baseline and changed to 204.75 ± 74.74 µm and 226.86 ± 90.77 µm at 2 and 6 months, respectively (p < 0.001 and p = 0.455). Twenty-two eyes (58%) gained ≥0.1 logMAR at 2 months, while 16 eyes showed no improvement. Low BCVA at symptom presentation, low baseline BCVA, and shorter duration of macular edema were correlated with increased BCVA after treatment. Conclusions The DEX implant improves functional and anatomical outcomes for up to 6 months in about half of the patients treated with IBI refractory macular edema secondary to BRVO, particularly in patients with low initial and baseline BCVA.

• Publication year

  2017

• Venue

  Korean Journal of Ophthalmology

• Publication date

  2017-03-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.3341/kjo.2017.31.2.108PMID 28367038PMCID 5368083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• INTRAVITREAL DEXAMETHASONE IMPLANT FOR THE TREATMENT OF REFRACTORY MACULAR EDEMA IN RETINAL VASCULAR DISEASES: Results of the KKESH International Collaborative Retina Study Group

  2016cited by this paper
• Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.

  2016cited by this paper
• Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab

  2015cited by this paper
• Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.

  2015cited by this paper
• Changes in choroidal thickness after intravitreal dexamethasone implant injection in retinal vein occlusion

  2015cited by this paper
• EFFICACY AND SAFETY OF TWO OR MORE DEXAMETHASONE INTRAVITREAL IMPLANT INJECTIONS FOR TREATMENT OF MACULAR EDEMA RELATED TO RETINAL VEIN OCCLUSION (SHASTA STUDY)

  2014cited by this paper
• VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).

  2014cited by this paper
• Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion

  2014cited by this paper
• Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.

  2014cited by this paper
• Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed

  2013cited by this paper
• Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

  2012cited by this paper
• Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials.

  2012influential reference
• Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

  2011cited by this paper
• Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration.

  2011cited by this paper
• Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

  2011cited by this paper
• Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

  2011cited by this paper
• Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

  2010cited by this paper
• Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion

  2010cited by this paper
• Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

  2010influential reference
• Natural history of branch retinal vein occlusion: an evidence-based systematic review.

  2010cited by this paper
• Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

  2010influential reference
• Enhanced Depth Imaging Optical Coherence Tomography of the Choroid in Normal Eyes

  2009cited by this paper
• Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion.

  2009cited by this paper
• A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.

  2009cited by this paper
• Changes of aqueous vascular endothelial growth factor and interleukin‐6 after intravitreal triamcinolone for branch retinal vein occlusion

  2008cited by this paper
• Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion

  2008cited by this paper
• Intravitreal bevacizumab (Avastin®) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial

  2008cited by this paper
• Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.

  2007influential reference
• Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study.

  1996cited by this paper
• Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7.

  1991cited by this paper
• Retinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular oedema.

  1984cited by this paper

• How to Judge Failure: Defining Treatment Resistance to Anti-VEGF Therapy in Exudative Maculopathies - A Systematic Scoping Review.

  2025cites this paper
• Predicting Treatment Response in Retinal Vein Occlusions Using Baseline Optical Coherence Tomography Biomarkers: A Systematic Review.

  2025cites this paper
• Visual outcomes and structural optical coherence tomography biomarkers after intravitreal dexamethasone implant for anti-vascular endothelial growth factor-resistant macular edema secondary to retinal vein occlusion

  2025cites this paper
• Intravitreal Dexamethasone Implant Switch after Anti-VEGF Treatment in Patients Affected by Retinal Vein Occlusion: A Review of the Literature

  2024cites this paper
• Efficacy of single-dose intravitreal dexamethasone implantation for retinal vein occlusion patients with refractory macular edema: A systematic review and meta-analysis

  2022cites this paper
• Predictors of Dexamethasone Response of Residual Edema by Branch Retinal Vein Occlusion after Bevacizumab Injection

  2022cites this paper
• Non-invasive monitoring of suprachoroidal, subretinal, and intravitreal implants using confocal scanning laser ophthalmoscope (cSLO) and optical coherence tomography (OCT).

  2021cites this paper
• Comparison of Ranibizumab versus Aflibercept in Treating Macular Edema among Patients with Serous Retinal Detachment Secondary to Branch Retinal Vein Occlusion

  2019cites this paper
• Clinical Use of Dexamethasone Implants in Resistant Macular Edema Secondary to Branch Retinal Vascular Occlusion Compared with Intravitreal Anti-Vascular Endothelial Growth Factor

  2019cites this paper
• Predictive Factors for a Favorable Response to Intravitreal Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion

  2018cites this paper